This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
by Ekta Bagri
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
biotechnology biotechs earnings-preview medical pharmaceuticals
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
biotechnology biotechs earnings medical pharmaceuticals
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
by Zacks Equity Research
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
biotechnology biotechs earnings medical pharmaceuticals
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
by Kaibalya Pravo Dey
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
biotechnology earnings insurance medical medical-devices pharmaceuticals
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
biotechnology biotechs medical pharmaceuticals
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
by Zacks Equity Research
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
by Zacks Equity Research
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
biotechnology biotechs medical pharmaceuticals